- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03633110
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- UC San Diego Moores Cancer Center
-
Santa Monica, California, United States, 90404
- John Wayne Cancer Institute - Providence Saint John's Health Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado, Anschutz Cancer Pavilion
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center - Herbert Irving Pavilion
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- The Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Carbone Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General Inclusion Criteria:
Diagnosis of 1 of the following tumor types:
- Melanoma (cutaneous).
- NSCLC.
- SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal).
- Urothelial carcinoma.
- Renal cell carcinoma (Part B only).
- Understand the study, be willing to comply with all study procedures and sign the informed consent
- Adequate tumor tissue available
- ECOG performance status of 0 or 1
- Negative pregnancy test (females of childbearing potential)
- Agree to use of contraception during the study until at least 90 days after final GEN-009 dose
- Adequate hematologic, liver, and kidney function
Part A-specific Inclusion:
- Have completed or will complete treatment for their disease with curative intent
- Have no evidence of disease
Part B-specific Inclusion:
Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below:
- NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel
- SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) ≥ 1.
- Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab.
Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who:
- Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS ≥ 10, or are not eligible for any platinum-containing chemotherapy, OR
- Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Renal Cell Carcinoma:
- Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR
- Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab.
- Disease assessment by CT or MRI
- Have at least 1 lesion that is measureable by RECIST 1.1
- Agree to a tumor biopsy 50 days after first GEN-009 vaccination
- Participants with hypothyroidism must be on thyroid replacement treatment
General Exclusion Criteria:
- Received a live vaccine ≤ 28 days, or a non-live vaccine ≤ 14 days, prior to the first dose of GEN-009
- Acute or chronic skin disorders that would interfere with injection
- Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable
- Allergy to the vaccine adjuvant Hiltonol (poly-ICLC)
- Active hepatitis B or hepatitis C infection
- HIV Positive
- History of clinically significant cardiac condition
- History of leptomeningeal carcinomatosis
- Had clinically active immune-mediated disease within 5 years
- Received a prior allogeneic stem cell transplant
- Has primary immune deficiency
- Received a prior solid organ transplant
- Has malignant disease, other than the tumor types being treated in this study
- Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until ≥ 90 days from last dose of GEN-009
- Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study
- Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis
Part A-specific Exclusion Criteria:
- Has received or requires more than 2 adjuvant or neoadjuvant regimens (other than surgical excisions) given with curative intent prior to first GEN-009 vaccination
- Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part A
Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy). Part A will consist of approximately 9 participants. |
GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
|
EXPERIMENTAL: Part B
Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab). Part B will consist of up to 90 participants. |
GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Other Names:
Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 1.5 years after first GEN-009 vaccination
|
Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
|
1.5 years after first GEN-009 vaccination
|
T-cell responses to GEN-009 adjuvanted vaccine
Time Frame: 1.5 years after first GEN-009 vaccination
|
Immunogenicity based on T-cell responses to GEN-009
|
1.5 years after first GEN-009 vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor activity of GEN-009 in Part B
Time Frame: 48 weeks after first GEN-009 vaccination
|
Evaluation conducted based on RECIST v1.1 (and immune-related RECIST [irRECIST], where appropriate)
|
48 weeks after first GEN-009 vaccination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term clinical outcomes of Part A participants
Time Frame: 1.5 years after first GEN-009 vaccination
|
Disease recurrence
|
1.5 years after first GEN-009 vaccination
|
Additional cellular responses after vaccination with GEN-009
Time Frame: 1 year after first GEN-009 vaccination
|
Cytokine secretion
|
1 year after first GEN-009 vaccination
|
Phenotype of circulating immune cells after vaccination with GEN-009
Time Frame: 1 year after first GEN-009 vaccination
|
Measured by flow cytometry
|
1 year after first GEN-009 vaccination
|
Tumor-infiltrating T cells after vaccination with GEN-009
Time Frame: 1 year after first GEN-009 vaccination
|
Will be examined in tumor biopsies
|
1 year after first GEN-009 vaccination
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Arthur P. DeCillis, MD
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Carcinoma, Squamous Cell
- Carcinoma, Renal Cell
- Carcinoma
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Pembrolizumab
Other Study ID Numbers
- GEN-009-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on GEN-009 Adjuvanted Vaccine
-
NovartisNovartis VaccinesCompletedInfluenza InfectionSwitzerland
-
SeqirusNovartis VaccinesCompleted
-
MedicagoCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesCanada
-
HenogenCompleted
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States, Belgium
-
Jiangsu Province Centers for Disease Control and...Hualan Biological Bacterin Co. Ltd.CompletedVirus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae InfectionsChina
-
GlaxoSmithKlineCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted